Ruck28 May 2020 01:14
Interesting post, and while for some odd reason I am having trouble sleeping, i thought I would respond to..........
""Now whether or not to lay that at the feet of the board is a matter of opinion and debate.
Not meant to be negative, just a statement of fact.""
Well I have never been one to lay the blame at the feet of the BOD, entirely, that IMHO with many other things is why I chose some time go to ignore after consideration the cackling of the ADVFN BB. Firstly and foremost, which is the reason I chose not to watch the news or read the Daily Press is because all they do is attach the blame for everything at the feet of whoever the shoe will fit, and "blame" is something I gladly grew out of some years ago, especially when it is done so in retrospect and create news at a time when the channels need something new to gossip about. That is not a political statement but I maintain when I want to hear news I want to hear what is happening now and not what should of happened in retrospect when everything like in life we would have done differently knowing the facts, that we know today.
I think Chiplin has been much maligned by posters without considering that when he took the helm the company was in a shambles, a deal had been lost and we needed a new stratagy. His response was to grow the company in key positions, where we had more scientists and senior staff making us a one stop shop, where we even had a manufacturing expert, Adrian Parry, in-house which essentially we could control and manufacture smaller doses for lab research at a fraction of the cost of outsourcing it.
It was done too to make us a better take over target where the company ""Scancell" was a small organisation which could easily be absorbed into a larger entity, rather than just being reliant on key person Lindy Durrant. With that obviously came a much larger overhead, which was probably calculated to do commercial deals in the mid term, say two years and be self financing., and above all be able to prepare for clinical trials far sooner. This has not happened, we can proportion some of that to the FDA, certainly in the last couple of years, MOD1 I feel has been targetted at big Pharma before clinical trial and the result of that has been one big u-turn to gather data as soon as possible to prove up our claims, in the absence of any commercial deals they might have planned for. I won"t delve into SCIB2, Avidamab and COVIDITY for the purpose of this post, other than to say in order, it is about time CRUK got this into trial, Avidamab we were always given a 12 month timeline with the first due in September and COVIDITY is something we are waiting on currently and all know the importance to Scancell.